Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival

Purpose: Even though recent studies have shown that genetic changes at enhancers can influence carcinogenesis, most methylomic studies have focused on changes at promoters. We used renal cell carcinoma (RCC), an incurable malignancy associated with mutations in epigenetic regulators, as a model to study genome-wide patterns of DNA methylation at a high resolution. Experimental Design: Analysis of cytosine methylation status of 1.3 million CpGs was determined by the HELP assay in RCC and healthy microdissected renal tubular controls. Results: We observed that the RCC samples were characterized by widespread hypermethylation that preferentially affected gene bodies. Aberrant methylation was particularly enriched in kidney-specific enhancer regions associated with H3K4Me1 marks. Various important underexpressed genes, such as SMAD6, were associated with aberrantly methylated, intronic enhancers, and these changes were validated in an independent cohort. MOTIF analysis of aberrantly hypermethylated regions revealed enrichment for binding sites of AP2a, AHR, HAIRY, ARNT, and HIF1 transcription factors, reflecting contributions of dysregulated hypoxia signaling pathways in RCC. The functional importance of this aberrant hypermethylation was demonstrated by selective sensitivity of RCC cells to low levels of decitabine. Most importantly, methylation of enhancers was predictive of adverse prognosis in 405 cases of RCC in multivariate analysis. In addition, parallel copy-number analysis from MspI representations demonstrated novel copy-number variations that were validated in an independent cohort of patients. Conclusions: Our study is the first high-resolution methylome analysis of RCC, demonstrates that many kidney-specific enhancers are targeted by aberrant hypermethylation, and reveals the prognostic importance of these epigenetic changes in an independent cohort. Clin Cancer Res; 20(16); 4349–60. ©2014 AACR.

[1]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[2]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[3]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[4]  O. Elemento,et al.  Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity , 2013, PLoS genetics.

[5]  E. Bottinger,et al.  Transforming growth factor-β, bioenergetics, and mitochondria in renal disease. , 2012, Seminars in nephrology.

[6]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[7]  Casalena Gabriella,et al.  Transforming Growth Factor Beta, Bioenergetics and Mitochondria in Renal Disease , 2012 .

[8]  Reid F. Thompson,et al.  Late-replicating heterochromatin is characterized by decreased cytosine methylation in the human genome. , 2011, Genome research.

[9]  K. Suszták,et al.  Transcriptome Analysis of Human Diabetic Kidney Disease , 2011, Diabetes.

[10]  N Clarke,et al.  Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma , 2011, Oncogene.

[11]  Reid F. Thompson,et al.  Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis , 2011, PLoS genetics.

[12]  Timothy J. Durham,et al.  "Systematic" , 1966, Comput. J..

[13]  B. Rini,et al.  Noncytotoxic differentiation treatment of renal cell cancer. , 2011, Cancer research.

[14]  Timothy J. Durham,et al.  Systematic analysis of chromatin state dynamics in nine human cell types , 2011, Nature.

[15]  T. Powles,et al.  Sunitinib and other targeted therapies for renal cell carcinoma , 2011, British Journal of Cancer.

[16]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[17]  Y. Kanai,et al.  Genetic and epigenetic alterations during renal carcinogenesis. , 2011, International journal of clinical and experimental pathology.

[18]  R. Büttner,et al.  Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma , 2010, Cancer science.

[19]  Esther Rheinbay,et al.  Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. , 2010, Cell stem cell.

[20]  Ralph Stadhouders,et al.  Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma , 2010, Nature Medicine.

[21]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[22]  C. Ricketts,et al.  Identification of Candidate Tumour Suppressor Genes Frequently Methylated in Renal Cell Carcinoma , 2009, Oncogene.

[23]  J. Nevins,et al.  Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. , 2009, Journal of Clinical Oncology.

[24]  R. Montironi,et al.  Prognostic role of global DNA‐methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens , 2009, Journal of cellular and molecular medicine.

[25]  Madeleine P. Ball,et al.  Corrigendum: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells , 2009, Nature Biotechnology.

[26]  Reid F. Thompson,et al.  High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers , 2009, Nucleic acids research.

[27]  Madeleine P. Ball,et al.  Targeted and genome-scale methylomics reveals gene body signatures in human cell lines , 2009, Nature Biotechnology.

[28]  Lucy Skrabanek,et al.  Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. , 2009, Blood.

[29]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[30]  W. Rathmell,et al.  VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy , 2009, Current oncology reports.

[31]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[32]  Brian Keith,et al.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.

[33]  Quan Chen,et al.  An analytical pipeline for genomic representations used for cytosine methylation studies , 2008, Bioinform..

[34]  M. van Engeland,et al.  Genetics and epigenetics of renal cell cancer. , 2008, Biochimica et biophysica acta.

[35]  Kenny Q. Ye,et al.  An Integrative Genomic and Epigenomic Approach for the Study of Transcriptional Regulation , 2008, PloS one.

[36]  M. Oya,et al.  Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. , 2007, The Journal of urology.

[37]  R. Verhaak,et al.  A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. , 2007, The Journal of clinical investigation.

[38]  Kenny Q. Ye,et al.  Comparative isoschizomer profiling of cytosine methylation: the HELP assay. , 2006, Genome research.

[39]  Jun Song,et al.  CEAS: cis-regulatory element annotation system , 2006, Nucleic Acids Res..

[40]  D. Melton,et al.  Notch signaling controls multiple steps of pancreatic differentiation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Figlin,et al.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  M. Esteller.  Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. , 2003, Advances in experimental medicine and biology.

[43]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[44]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[45]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[46]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.